What is the address of PHARMA SOLUTIONS?

The registered office of PHARMA SOLUTIONS is located at Vijfstraten 209, 9100 Sint-Niklaas.

Is PHARMA SOLUTIONS still active?

Yes. According to the CBE (2 November 2026) PHARMA SOLUTIONS is active, legal situation “Normale toestand”, started on 21 December 1999.

Is PHARMA SOLUTIONS registered on Peppol?

Yes, PHARMA SOLUTIONS is registered on the Peppol network with ID 0208:0468526628.

What is the enterprise number of PHARMA SOLUTIONS?

The enterprise number of PHARMA SOLUTIONS is BE0468526628.

When was PHARMA SOLUTIONS founded?

PHARMA SOLUTIONS was founded on 21 December 1999.

Who are the directors of PHARMA SOLUTIONS?

According to the 2025 annual accounts, the directors of PHARMA SOLUTIONS are: Bart Waelput.

Is PHARMA SOLUTIONS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 21 December 1999; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMA SOLUTIONS make in 2025?

PHARMA SOLUTIONS posted a profit after taxes of € 59,656 in financial year 2025.

What is the revenue of PHARMA SOLUTIONS?

As a small company, PHARMA SOLUTIONS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 90,741.

How many employees does PHARMA SOLUTIONS have?

According to the 2025 annual accounts, PHARMA SOLUTIONS has 0 full-time equivalents (FTE).

PHARMA SOLUTIONS (Public Limited) - Sint-Niklaas

Q: What does PHARMA SOLUTIONS do?

PHARMA SOLUTIONS is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Public Limited, started on 21 December 1999, 1 establishment.

Dossier PHARMA SOLUTIONS, printed on 3 November 2026 from databakkes.be/en/0468526628/pharma-solutions. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMA SOLUTIONS from Sint-Niklaas, company number BE0468526628, closed financial year 2025 with a result of € 59,656 after tax. For that financial year PHARMA SOLUTIONS recorded a gross margin of € 90,741 and equity of € 158,716. Compared with financial year 2024, the result moved from € 65,461 to € 59,656. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 15, 2026.

What it is worth Growing

€ 158,716

▲ 60% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 59,656

▼ 9% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 76,785

▲ 100% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 89,285.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 18,523

▲ 54% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 8,517

▼ 13% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 12,167 Gross margin 2022: € 12,167 First fiscal year in the series	€ 98,961 Gross margin 2023: € 98,961 ▲ € 86,794 vs 2022 (€ 12,167) Favourable step	€ 81,126 Gross margin 2024: € 81,126 ▼ 18% vs 2023 (€ 98,961) Unfavourable step	€ 90,741 Gross margin 2025: € 90,741 ▲ 12% vs 2024 (€ 81,126) Favourable step	▲ 12%
Profit after taxes	€ -10,589 Profit after taxes 2022: € -10,589 First fiscal year in the series	€ 25,984 Profit after taxes 2023: € 25,984 ▲ € 36,573 vs 2022 (€ -10,589) Favourable step	€ 65,461 Profit after taxes 2024: € 65,461 ▲ 152% vs 2023 (€ 25,984) Favourable step	€ 59,656 Profit after taxes 2025: € 59,656 ▼ 9% vs 2024 (€ 65,461) Unfavourable step	▼ 9%
Equity	€ 7,615 Equity 2022: € 7,615 First fiscal year in the series	€ 33,599 Equity 2023: € 33,599 ▲ € 25,984 vs 2022 (€ 7,615) Favourable step	€ 99,060 Equity 2024: € 99,060 ▲ 195% vs 2023 (€ 33,599) Favourable step	€ 158,716 Equity 2025: € 158,716 ▲ 60% vs 2024 (€ 99,060) Favourable step	▲ 60%
Total debts	€ 368,105 Total debts 2022: € 368,105 First fiscal year in the series	€ 347,901 Total debts 2023: € 347,901 ▼ 5% vs 2022 (€ 368,105) Favourable step	€ 178,021 Total debts 2024: € 178,021 ▼ 49% vs 2023 (€ 347,901) Favourable step	€ 235,843 Total debts 2025: € 235,843 ▲ 32% vs 2024 (€ 178,021) Unfavourable step	▲ 32%
Cash	€ 8,138 Cash 2022: € 8,138 First fiscal year in the series	€ 44,331 Cash 2023: € 44,331 ▲ € 36,193 vs 2022 (€ 8,138) Favourable step	€ 38,340 Cash 2024: € 38,340 ▼ 14% vs 2023 (€ 44,331) Unfavourable step	€ 76,785 Cash 2025: € 76,785 ▲ 100% vs 2024 (€ 38,340) Favourable step	▲ 100%
Land & buildings	€ 130,905 Land & buildings 2022: € 130,905 First fiscal year in the series	€ 124,612 Land & buildings 2023: € 124,612 ▼ 5% vs 2022 (€ 130,905) Unchanged	€ 118,428 Land & buildings 2024: € 118,428 ▼ 5% vs 2023 (€ 124,612) Unchanged	€ 112,355 Land & buildings 2025: € 112,355 ▼ 5% vs 2024 (€ 118,428) Unchanged	▼ 5%
Retained profit	€ -61,816 Retained profit 2022: € -61,816 First fiscal year in the series	€ -35,832 Retained profit 2023: € -35,832 ▲ € 25,984 vs 2022 (€ -61,816) Favourable step	€ 29,629 Retained profit 2024: € 29,629 ▲ € 65,461 vs 2023 (€ -35,832) Favourable step	€ 89,285 Retained profit 2025: € 89,285 ▲ 201% vs 2024 (€ 29,629) Favourable step	▲ 201%
Balance sheet total	€ 375,720 Balance sheet total 2022: € 375,720 First fiscal year in the series	€ 381,500 Balance sheet total 2023: € 381,500 ▲ 2% vs 2022 (€ 375,720) Unchanged	€ 277,081 Balance sheet total 2024: € 277,081 ▼ 27% vs 2023 (€ 381,500) Unchanged	€ 394,559 Balance sheet total 2025: € 394,559 ▲ 42% vs 2024 (€ 277,081) Unchanged	▲ 42%

Key figures of PHARMA SOLUTIONS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMA SOLUTIONS?

What happened at PHARMA SOLUTIONS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 15, 2026 New annual accounts for financial year 2025: profit of € 59,656 (▼ 9% vs 2024). filed late Source: NBB ↗
2023 Bart Waelput became a director. NBB
Feb 7, 2000 New establishment in Beveren-Kruibeke-Zwijndrecht. KBO
Dec 21, 1999 Start of the company according to the CBE. KBO

In short

From € 10,589 loss in 2022 to € 59,656 profit in 2025.

Paid € 29,589 in corporate taxes since 2022.

Best year ever: 2024, with € 65,461 profit.

Original PDFs at the National Bank ↗

Management

Apotheek Waelput 10%

The stake of Apotheek Waelput comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARMA SOLUTIONS

Behind PHARMA SOLUTIONS is Bart Waelput. The shares are held by Apotheek Waelput (10%).

Directors

According to the 2025 annual accounts

Bart Waelput

Director

Also active at: DRIEKONINGEN, Apotheek Waelput, FARMA WAELPUT, Waelput Invest

since 2023

Shareholders

Apotheek Waelput

10%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Vijfstraten 209

9100 Sint-Niklaas

2.094.875.148

Wolfsbergstraat 6

2070 Beveren-Kruibeke-Zwijndrecht

Active since 7 February 2000

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

FARMA - BOVAN

€ -147 gross margin · 2025

Waelput Invest same network

€ 524,180 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0468.526.628

VAT number

BE 0468.526.628

Registered office

Vijfstraten 209, 9100 Sint-Niklaas

Names & denominations

PHARMA SOLUTIONS

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

21 December 1999

Peppol

Active · Active since 12 Jan 2026

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsvoering en beheer

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMA SOLUTIONS

Financials

What happened to PHARMA SOLUTIONS?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions